OncoMatch/Clinical Trials/NCT06767527

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Is NCT06767527 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including AK112 and Nab-paclitaxel for triple-negative breast cancer (tnbc).

Phase 3RecruitingAkesoNCT06767527Data as of May 2026

Treatment: AK112 · Nab-paclitaxel — This multicenter, randomized, double-blind study aims to assess the safety and efficacy of AK112 in combination with Nab-Paclitaxel, compared to a placebo plus Nab-Paclitaxel, as a first-line treatment for inoperable locally advanced or metastatic triple-negative breast cancer (TNBC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Biomarker criteria

Required: ESR1 negative

negative status for ER

Required: PR (PGR) negative

negative status for PR

Required: HER2 (ERBB2) negative

negative status for HER-2

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify